These results indicate that targeting GSK-3β (with SB216763 alone or combined with anti-CD47 antibody treatment) can decrease the CD47 expression and apoptosis rate during MI, thereby preserving cardiac function. This evidence concerns the gene CD47 and myocardial infarction.